Sefazolin etkileşimleri

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Ertapenem etiketi, Kontrendikasyonlar)

Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. (İmipenem ve silastatin etiketi, Uyarılar ve önlemler)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Co-administration of probenecid with Cefazolin for Injection is not recommended. (Sefazolin etiketi, İlaç etkileşimleri)

Co-administration of probenecid with Cefazolin for Injection is not recommended. (Sefazolin etiketi, İlaç etkileşimleri)

Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. (Rifampisin etiketi, Uyarılar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Sefazolin etiketi, Kontrendikasyonlar)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefazolin etiketi, Uyarılar ve önlemler)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefazolin etiketi, Uyarılar ve önlemler)

Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Aztreonam etiketi, Uyarılar ve önlemler)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefazolin etiketi, Uyarılar ve önlemler)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefazolin etiketi, Uyarılar ve önlemler)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefazolin etiketi, Uyarılar ve önlemler)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefazolin etiketi, Uyarılar ve önlemler)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Etakrinik asit etiketi, İlaç etkileşimleri)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (Sefazolin etiketi, Uyarılar ve önlemler)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefazolin etiketi, Uyarılar ve önlemler)

Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. (Furosemid etiketi, İlaç etkileşimleri)

Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. (Gentamisin etiketi, İlaç etkileşimleri)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefazolin etiketi, Uyarılar ve önlemler)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (Sefazolin etiketi, Uyarılar ve önlemler)

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (Mikofenolat etiketi, İlaç etkileşimleri)

Drug Interactions Protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins (see DOSAGE AND ADMINISTRATION ). (Protamin etiketi, Önlemler)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefazolin etiketi, Uyarılar ve önlemler)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Sefazolin etiketi, Uyarılar ve önlemler)

Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. (Aminofilin etiketi, İlaç etkileşimleri)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Before initiating therapy with Meropenem for injection, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. (Meropenem etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Some drugs (e.g. cefazolin, cephalothin), however, may interfere with certain HPLC techniques. (Teofilin etiketi, İlaç etkileşimleri)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Sefazolin etiketi, Uyarılar ve önlemler)